Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Agree to not initiate or change use of orthotics or inserts designed to relieve symptoms of plantar fibromatosis during the study period.
Do you have at least one hard, firm nodule on the sole of your foot?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1) to days 15, 29, 43, 57
Awards & highlights
Study Summary
This trial will study whether a new drug, EN3835, is effective and safe for treating plantar fibromatosis.
Eligible Conditions
- Plantar Fibroma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
Do not start using orthotics or inserts specifically designed to treat plantar fibromatosis during the study period.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline (day 1) to days 15, 29, 43, 57
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1) to days 15, 29, 43, 57
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Mean Change between EN3835 and placebo in the Foot Function Index (FFI) pain subscale
Secondary outcome measures
Change in the proportion of EN3835-treated participants and those receiving only placebo reporting a 7-point scale Clinician Global Impression of Change Scale
Mean Change with EN3835 and placebo in the FFI pain subscale
Mean change between EN3835 and placebo in the nodular hardness of the treated nodules by durometer measurement
+5 moreSide effects data
From 2021 Phase 3 trial • 153 Patients • NCT0417029693%
Injection site bruising
79%
Injection site pain
33%
Injection site discolouration
19%
Injection site pruritus
18%
Injection site swelling
7%
Injection site oedema
7%
Injection site nodule
7%
Injection site mass
3%
Injection site haemorrhage
3%
Post-inflammatory pigmentation change
1%
Diffuse alopecia
1%
Urinary tract infection
1%
Coronavirus test positive
1%
Blood potassium increased
1%
White blood cell count increased
1%
Nitrite urine present
1%
Urine leukocyte esterase positive
1%
Oropharyngeal pain
1%
Injection site dermatitis
1%
Pyrexia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cohort 2: Buttocks
Cohort 1: Posterolateral Thigh
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: EN3835 GroupExperimental Treatment1 Intervention
Participant will receive a maximum dose of up to 1.8mg of EN3835 injection
Group II: Placebo GroupPlacebo Group1 Intervention
Participant will receive a maximum dose of up to 1.8mg of Placebo injection
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EN3835
2019
Completed Phase 3
~1540
Find a Location
Who is running the clinical trial?
Endo PharmaceuticalsLead Sponsor
133 Previous Clinical Trials
34,819 Total Patients Enrolled
Nina GreenStudy DirectorEndo Pharmaceuticals
1 Previous Clinical Trials
145 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What state do they live in?
Virginia
Kentucky
Texas
Other
How old are they?
18 - 65
65+
What site did they apply to?
Endo Clinical Trial Site #10
Endo Clinical Trial Site #36
Endo Clinical Trial Site #30
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How responsive is this trial?
Typically responds via
Phone Call
Most responsive sites:
- Endo Clinical Trial Site #36: < 48 hours
Average response time
- < 2 Days
Recent research and studies
Share this study with friends
Copy Link
Messenger